The PREVENT-COVID in Seniors Study: PRospEctiVe EvaluatioN of immuniTy after COVID-19 vaccines in Seniors [PREVENT-COVID-19, study data contributed to the CITF Databank]

<b>Background:</b> There is evidence that suggests that vaccines are effective against infection, but it is unclear how age and certain antibodies from previous infections influence their level of effectiveness. <br>

<b>Aims of the CITF-funded study:</b> This study aimed to compare short-term and long-term immune responses to COVID-19 vaccines among older adults and seniors. Specifically, they aimed to compare the antibody levels, quantity, and function after vaccination by vaccine type and age. <br>

<b>Methods:</b> This cohort study enrolled participants in British Columbia who were receiving their first or second dose of the BNT162b2 (Pfizer), mRNA-1273 (Moderna), or ChAdOx1-S COVID-19 vaccine and over the age of 19, pivoting to oversampling older adults (50+) to address high-priority knowledge gaps. Participants answered an online questionnaire at baseline and provided a blood sample via DBS or venipuncture at baseline and at each follow up (7 times at regular intervals). <br>

<b>Contributed dataset contents:</b> The datasets include 772 participants who completed baseline surveys between February 2021 and May 2022. 96% of these participants gave one or more blood samples between February 2021 and June 2023. A total of 3564 samples were collected. Variables include data in the following areas of information: demographics (date of birth, sex, gender, ethnicity), general health (weight and height, flu vaccine, medical conditions), SARS-CoV-2 vaccination, and serology (antibodies against SARS-CoV-2 RBD, nucleocapsid, and spike proteins).